2020
DOI: 10.1126/scitranslmed.aaz7423
| |Summarize |Cite
|
Sign up to set email alerts

Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy

Abstract: REVERSE is a randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial that evaluated the efficacy of a single intravitreal injection of rAAV2/2-ND4 in subjects with visual loss from Leber hereditary optic neuropathy (LHON). A total of 37 subjects carrying the m.11778G>A (MT-ND4) mutation and with duration of vision loss between 6 to 12 months were treated. Each subject’s right eye was randomly assigned in a 1:1 ratio to treatment with rAAV2/2-ND4 (GS010) or sham injection. The left ey… Show more

Search citation statements

Order By: Relevance

Paper Sections

Select...
198
42
31
11

Citation Types

8
261
0
0

Year Published

Range
2000
2000
2026
2026

Publication Types

Select...
222
19
9
2

Relationship

34
218

Authors

Journals

Cited by 250 publications

(269 citation statements)

References 46 publications

8
261
0
0
Order By: Relevance
How the paper below cites the one you are viewing
“…Although this does not demonstrate an absence of vector distribution to the CNS, it is supportive of the long-term safety of lenadogene nolparvovec. These results consistent with the previously reported favorable safety profile of lenadogene nolparvovec and the absence of CNS adverse reactions [11][12][13].…”
Section: Discussion
supporting
confidence: 92%
“…Thus, this study indicates that the tumor occurrence was unrelated to lenadogene nolparvovec. These results confirm the favorable safety profile of lenadogene nolparvovec gene therapy in MT-ND4 LHON treated patients [11][12][13].…”
Section: Discussion
supporting
confidence: 79%
See 1 more Smart Citation